HLA-C and neoplasm: Among the resistant mechanisms involving the DDR in response to immune checkpoint therapy, several factors can be distinguished including low neoantigen burden, low PD-L1 expression in certain types of tumors, down-regulated tumor MHC expression, recruitment of immunosuppressive cells, and the release of cytokines in the tumor milieu.